{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:27Z","timestamp":1790666547560,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Objective<\/jats:title>\n Sacituzumab govitecan (SG) has emerged as a therapeutic option for various cancers. Increasing reports of SG-associated neutropenia have attracted attention, emphasizing the need to fully characterize this risk.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study conducted a retrospective pharmacovigilance analysis using the Food and Drug Adverse Event Reporting System (FAERS) database. Cases of neutropenia associated with SG were extracted from the second quarter of 2020 through the second quarter of 2025 for disproportionality analysis. Additionally, a meta-analysis was performed on randomized controlled trials (RCTs) comparing SG (experimental group) with chemotherapy drugs (control group), retrieved from CNKI, Wanfang, VIP, PubMed, the Cochrane Library, EMBASE, and Web of Science.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the FAERS, 500 cases of neutropenia were associated with SG treatment. Among antibody-drug conjugate (ADC) drugs, SG exhibited the strongest positive signal (reported odds ratio (ROR) = 17.91, 95% CI: 16.39\u201319.56). Subgroup analysis revealed that this signal widely existed in different gender, age, reporting groups and initial indications. Most events occurred within 30 days of initial initiation. Gender (10 days for males vs. 13 days for females,\n P<\/jats:italic>\n &lt; 0.05) and initial indications (12 days for breast cancer\/lung cancer vs. 8 days for bladder cancer,\n P<\/jats:italic>\n &lt; 0.05) were significantly associated with time-to-onset. Five RCTs were included in this meta-analysis. The results showed that for all adverse event (AE) grades, SG is associated with an increased risk of neutropenia (odds ratio (OR) = 2.07, 95% CI: 1.09\u20133.93,\n P<\/jats:italic>\n &lt; 0.05). Subgroup analysis indicated that SG significantly increased the risk of all-grade neutropenia AE in patients with breast cancer (OR = 2.13, 95% CI: 1.68\u20132.69,\n P<\/jats:italic>\n &lt; 0.00001), and a similar trend was observed among bladder cancer patients (\n P<\/jats:italic>\n &lt; 0.00001). Although no significant difference emerged in the risk of all-grade AEs for lung cancer patients (\n P<\/jats:italic>\n &gt; 0.05), the control group exhibited a tendency toward higher risk, and the SG group demonstrated a significantly lower incidence of grade \u22653 AEs compared to controls (\n P<\/jats:italic>\n &lt; 0.05). In addition, the risk of neutropenia did not differ significantly between patients with the UGT1A1\n *<\/jats:sup>\n 1\/\n *<\/jats:sup>\n 28 and UGT1A1\n *<\/jats:sup>\n 28\/\n *<\/jats:sup>\n 28 genotypes compared to those with the UGT1A1\n *<\/jats:sup>\n 1\/\n *<\/jats:sup>\n 1 genotype (\n P<\/jats:italic>\n &gt; 0.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The combined analysis supports an elevated risk of neutropenia associated with SG. This AE exhibits significant cancer species specificity. Early intervention and management of neutropenia are therefore of considerable clinical importance.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2025.1714638","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:11:10Z","timestamp":1768205470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yin-Xue","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Fen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Wen","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/10781552211057486","article-title":"Case report of Sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype","volume":"28","author":"Baek","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. Journal Medicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an Anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B7","unstructured":"US prescribing information: Sacituzumab govitecan. [EB\/OL]. [2025-9-22]"},{"key":"B8","unstructured":"Food and drug administration FDA adverse event reporting system (FAERS) public dashboard. [EB\/OL]. [2025-9-22]"},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","article-title":"Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA","volume":"27","author":"Fukazawa","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1001\/jama.274.22.1800","article-title":"Users' guides to the medical literature. IX. A method for grading health care recommendations","volume":"274","author":"Guyatt","year":"1995","journal-title":"Evidence-Based Med. Work. Group. Jama"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1002\/ptr.6477","article-title":"The effects of curcumin supplementation on endothelial function: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"33","author":"Hallajzadeh","year":"2019","journal-title":"Phytotherapy Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41431-023-01315-x","article-title":"Correction: Dutch pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction between UGT1A1 and irinotecan","volume":"31","author":"Hulshof","year":"2023","journal-title":"Eur. Journal Human Genetics EJHG."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","article-title":"Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan\u2010induced neutropenia in Asian cancer patients","volume":"98","author":"Jada","year":"2007","journal-title":"Cancer Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/OP.21.00624","article-title":"All you need to know about UGT1A1 genetic testing for patients treated with irinotecan_ a practitioner-friendly guide","volume":"18","author":"Karas","year":"2022","journal-title":"JCO Oncology Practice"},{"key":"B18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/14740338.2023.2223955","article-title":"Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA adverse event reporting system database (FAERS)","volume":"22","author":"Mytheen","year":"2023","journal-title":"Expert Opinion Drug Safety"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/cancers13071566","article-title":"UGT1A1 guided cancer therapy: review of the evidence and considerations for clinical implementation","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000525351","article-title":"Neutropenic enterocolitis: a rare complication of Sacituzumab govitecan","volume":"15","author":"Prescott","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1447280","DOI":"10.3389\/fimmu.2024.1447280","article-title":"Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"Npj Breast Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with Sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an Anti-Trop-2\u2013SN-38 antibody conjugate (Sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B30","unstructured":"Cochrane handbook systematic reviews interventions. version 5.1.0. [EB\/OL]. [2025-9-22]\n \n \n 2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3949\/ccjm.75.6.431","article-title":"Meta-analysis: its strengths and limitations","volume":"75","author":"Walker","year":"2008","journal-title":"Cleve Clin. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2\u2212 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:11:13Z","timestamp":1768205473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":33,"alternative-id":["10.3389\/fphar.2025.1714638"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1714638","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1714638"}}